Skip to content
Home/Companies/Healthcare/Amyl Therapeutics

Amyl Therapeutics

Healthcare·Belgium·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Amyl Therapeutics?

Amyl Therapeutics is currently owned by Merieux Equity Partners through Mérieux Innovation 1 (2014 vintage), since 2021.

Hand-verified · updated 2026-05-07

Merieux Equity Partners
Investor
Merieux Equity Partners
Mérieux Innovation 1 · 2014 · VC

Key facts

HQEurope
SectorHealthcare
StatusActive

More from Mérieux Innovation 1

Other portfolio companies in the same fund.

Broken String Biosciences
Broken String Biosciences
Active
HealthcareUK· 2023
InnoSyn
InnoSyn
Active
HealthcareNetherlands· 2023
LabQuality
LabQuality
Exited 2025
HealthcareFrance· 2023
to
Cairdac
Cairdac
Active
MedTechFrance· 2022
Mablink Bioscience
Exited 2023
BiotechFrance· 2022
to
SeqOne Genomics
SeqOne Genomics
Active
BiotechFrance· 2022

More PE-backed in Healthcare

Comparable healthcare deals from other GPs.

3i – Implant Innovations Inc.
Active
Advent InternationalUS
Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
Abode Healthcare
Active
Summit PartnersUS
AccentCare
AccentCare
Active
Advent InternationalUS
Acentra Health
Acentra Health
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Track Amyl Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Amyl Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Amyl Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue